Abstract: Objective To investigate the efficacy of recombinant human erythropoietin (rHuEPO) on reverse left ventricular hypertrophy (LVH) by improving anemia in chronic renal insufficiency (CRI) patients.Method Fifty-one patients who were diagnosed as CRI withont receiving renal replacement therapy were randomly divided into two groups, Treatment group (group T) and control group (group C). In group T the 26 patients were given rHuEPO 100～120U/Kg/wk through hypodermic injection at beginning, when the hemoglobin (Hb) reached 105～115g/L and the hematocrit (Hct) was 30%～50%, the dose of rHuEPO should decreased to maintenance dose, In (group C) the 25 patients didn’t receive rHuEPO therapy the blood pressure of all patients in the two groups were at the normal or near normal level during the treatment. The two groups' Hb、Hct、left ventricular mass index(LVMI)、systolic blood pressure(SBP)、diastolic blood pressure(DBP) and endogenous creatinine clearance(Ccr) were compared.Results ①There were no significant change in SBP、DBP and Ccr between the two groups after the treatment. ②Hb and Hct increased significantly in group T after treatment(P＜0.01). ③LVMI in group T after treatment were lower than that before treatment and in group C(P＜0.01). ④There were no significant difference of the blood pressure in two groups(P＞0.05). Conclusions rHuEPO therapy can reverse LVH through rectify the anemia of CRI patients.

Key words: Anemia, Left ventricular hypertrophy